Visual Hallucinations Treated with the Reinitiation of Memantine in a Patient with Lewy Body Dementia (February).

< Texas Tech University Health Sciences Center, Dallas.
Annals of Pharmacotherapy (Impact Factor: 2.06). 02/2013; 47(2). DOI: 10.1345/aph.1R522
Source: PubMed


To report on a patient with Lewy body dementia who developed worsening of hallucinations with memantine withdrawal and significant improvement with reinitiation of the drug.

Case summary:
A 78-year-old man presented to a geriatric psychiatry clinic in March 2011. The patient had experienced gradual memory loss since 2007 and was diagnosed with dementia with Lewy bodies (DLB) in 2009. His medication regimen included donepezil and memantine; his cognitive and functional status appeared stable. Occasional mild visual hallucinations occurred but were not concerning to the patient or his wife. The patient did well to July 2011, when memantine became restricted within the health care institution; memantine was therefore tapered to discontinuation. From July to September 2011, the patient's cognition and function appeared to decline significantly. He also began experiencing severe visual hallucinations daily. Memantine was reinitiated in September 2011 and, within days, the patient was free of hallucinations. By November 2011, his cognition and function were noted to have improved to previous status, and hallucinations were rare.

Three small randomized studies and 4 case reports were found addressing the use of memantine for DLB. Both improvement and worsening of hallucinations were noted with memantine use in the case reports, but the studies showed only a small benefit in cognition. However, cognitive and psychiatric symptoms worsened when memantine was discontinued. One study found that Neuropsychiatric-Inventory scores and hallucination scores improved significantly for patients taking memantine.

The literature investigating the use of memantine for the psychiatric symptoms of DLB is limited but there are data noting results similar to what we observed in our patient when his memantine was discontinued and reinitiated.

36 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of visual hallucinations in neurodegenerative disorders is not well advanced. The complexity of underlying mechanisms presents a number of potential avenues for developing treatments, but also suggests that any single one may be of limited efficacy. Reducing medication, with the careful introduction of antidementia medication if needed, is the mainstay of current management. Antipsychotic medication leads to excessive morbidity and mortality and should only be used in cases of high distress that do not otherwise respond. Education, reduction of risk factors and psychological treatments have limited evidence of efficacy, but are unlikely to cause harm.
    Future Neurology 07/2013; 8(4):433-444. DOI:10.2217/fnl.13.19
  • Source
    Journal of Clinical Psychopharmacology 10/2014; · 3.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ingestion of drugs or plant chemicals that advertently or inadvertently induce visual hallucination (VH) provides a basis for understanding VH mechanisms and selecting or designing counteracting drugs or hallucinolytic agents. This review explores the broad range and nature of medical and recreational or ritualistic drugs which are hallucinogenic, and alternative avenues for treatment, based on pharmacotherapy, psychological or other interventions. In relation to disease, VH are experienced in a range of psychiatric and neurological conditions, as well as in non-CNS or brain disorders. Epilepsy, Parkinson's disease (PD) and Lewy body dementia (LBD), together with schizophrenia, are prominent neurological or psychiatric conditions in which VH are common. In neurologically or psychiatrically normal individuals, VH are associated with eye disease, leading to the Charles Bonnet syndrome, and with delirious states arising from infections, surgical interventions, and withdrawal of alcohol or benzodiazepines, for example.
    The Neuroscience of Visual Hallucinations, 12/2014: pages 321-341; , ISBN: 9781118731703
Show more


36 Reads
Available from